Literature DB >> 24911354

HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.

Niamh M Keane1, Rebecca K Pavlos, Elizabeth McKinnon, Andrew Lucas, Craig Rive, Christopher C Blyth, David Dunn, Michaela Lucas, Simon Mallal, Elizabeth Phillips.   

Abstract

OBJECTIVES: This study sought to examine nevirapine hypersensitivity (NVP HSR) phenotypes and their relationship with differing major histocompatibility complex (MHC) Class I and Class II alleles and the associated CD4 and CD8 T-cell NVP-specific responses and their durability over time.
METHODS: A retrospective cohort study compared HIV-positive patients with NVP HSR, defined by fever and hepatitis and/or rash, with those tolerant of NVP for more than 3 months. Covariates included class I (HLA-A, B, C) and class II (HLA-DR) alleles. Cellular studies examined NVP-specific CD4 and CD8 T-cell responses by interferon-gamma (IFNγ) ELISpot assay and intracellular cytokine staining (ICS).
RESULTS: NVP HSR occurred in 19 out of 451 (4%) NVP-exposed individuals between March 1993 and December 2011. HLA associations were phenotype dependent with HLA-DRB1*01 : 01 associated with hepatitis (P = 0.02); HLA-B*35 : 01 and HLA-Cw4 associated with cutaneous NVP HSR (P = 0.001, P = 0.01), and HLA-Cw*08 was associated with NVP HSR with eosinophilia (P = 0.04) and multisystemic NVP HSR (P = 0.02). NVP-specific INFγ responses waned significantly more than 3 months from the original reaction and were diminished or completely abrogated when either CD4 or CD8 T cells were depleted from the peripheral blood mononuclear cells culture.
CONCLUSION: The association of specific class I and II allele pairings with specific phenotypes of NVP HSR, and cellular studies showing both CD4 and CD8 T-cell NVP-specific responses suggest that specific combinations of NVP reactive class I restricted CD8 and class II restricted CD4 T cells contribute to the immunopathogenesis of NVP HSR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911354     DOI: 10.1097/QAD.0000000000000345

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

Review 1.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

2.  Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.

Authors:  Mark Thomas; Chris Hopkins; Eamon Duffy; Daniel Lee; Pierre Loulergue; Diego Ripamonti; David A Ostrov; Elizabeth Phillips
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

3.  HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.

Authors:  Katherine C Konvinse; Jason A Trubiano; Rebecca Pavlos; Ian James; Christian M Shaffer; Cosmin A Bejan; Ryan J Schutte; David A Ostrov; Mark A Pilkinton; Misha Rosenbach; Jeffrey P Zwerner; Kristina B Williams; Jack Bourke; Patricia Martinez; Francois Rwandamuriye; Abha Chopra; Mark Watson; Alec J Redwood; Katie D White; Simon A Mallal; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol       Date:  2019-02-16       Impact factor: 10.793

4.  Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.

Authors:  Ylva Terelius; Robert A Figler; Svetlana Marukian; Maria S Collado; Mark J Lawson; Aaron J Mackey; David Manka; Charles W Qualls; Brett R Blackman; Brian R Wamhoff; Ajit Dash
Journal:  Chem Biol Interact       Date:  2015-12-02       Impact factor: 5.192

Review 5.  T cell-mediated hypersensitivity reactions to drugs.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Soren Buus; Imir Metushi; Bjoern Peters; Elizabeth Phillips
Journal:  Annu Rev Med       Date:  2014-10-27       Impact factor: 13.739

Review 6.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

Review 7.  Antiviral drug allergy.

Authors:  Brigitte Milpied-Homsi; Ellen M Moran; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2014-08       Impact factor: 3.479

8.  The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.

Authors:  Jason A Trubiano; Kaija Strautins; Alec J Redwood; Rebecca Pavlos; Katherine C Konvinse; Ar Kar Aung; Monica A Slavin; Karin A Thursky; M Lindsay Grayson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017-10-31

9.  Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions.

Authors:  Jason A Trubiano; Kyra Y L Chua; Natasha E Holmes; Abby P Douglas; Effie Mouhtouris; Michelle Goh; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2019-10-31

Review 10.  HLAs: Key regulators of T-cell-mediated drug hypersensitivity.

Authors:  A J Redwood; R K Pavlos; K D White; E J Phillips
Journal:  HLA       Date:  2018-01       Impact factor: 4.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.